المؤلفون: Iqra Mushtaq, Aneeqa Mumtaz, Iram Manzoor

المصدر: Pakistan Armed Forces Medical Journal, Vol 71, Iss 5, Pp 1889-1892 (2021)

مصطلحات موضوعية: medicine.medical_specialty, Medicine (General), exercise, business.industry, Diastole, Sitting diastolic blood pressure, blood pressure, Sitting systolic blood pressure, body mass index, Sitting, Correlation, Blood pressure, R5-920, Correlational study, Internal medicine, medicine, Cardiology, Medicine, business, Body mass index

الوصف: Objective: To find out correlation of body measurements and exercise with blood pressure among medical students in Lahore, Pakistan. Study Design: Correlational study. Place and Duration of Study: Akhtar Saeed Medical and Dental College, Lahore, from May to Jul 2018. Methodology: A sample of 332 students was recruited through simple random sampling technique. Resting blood pressure in sitting position along with body mass index of respondents were taken after informed consent. Results: Mean age of respondents was 21.06 ± 1.53 years. Mean sitting systolic blood pressure was 117.5 ± 8.24mm Hg, Mean sitting diastolic blood pressure was 77.9 ± 7.05mm Hg. Significant association was found between weight and both Systolic (r=1, p≤0.00) and Diastolic (r=0.01, p=0.05) blood pressure. Height was negatively correlated with systolic blood pressure (r=-0.004) and diastolic blood pressure (r=-0.07). Body mass index was also significantly associated with systolic blood pressure (r=1, p≤0.00) and diastolic blood pressures (r=0.14, p=0.00). Significant association is found between systolic blood pressure and exercise with number of days (r=-0.15, p=0.05) and diastolic blood pressure (r=-0.11, p=0.00) and duration of exercise with systolic blood pressure (r=-0.13, p=0.01) and diastolic blood pressure (r=-0.16, p=0.04). Conclusion: Weight and Body mass index are positively correlated with systolic and diastolic blood pressure.Keywords: , , , .

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4f978762926eb8f0f8d87ac133cfe6dTest
https://www.pafmj.org/index.php/PAFMJ/article/view/6089/3644Test

المؤلفون: Hyuck Moon Kwon, Chang Gyu Park, Kwang Je Lee, Byung Su Yoo, Gyu Chul Oh, In Jai Kim, Seong Hoon Park, Seung Hwan Han, Gyo-Seung Hwang, Hyo-Soo Kim

المصدر: Drug Design, Development and Therapy

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, hypertension, Time Factors, Pharmaceutical Science, Blood Pressure, 030204 cardiovascular system & hematology, Essential hypertension, Severity of Illness Index, Clinical study, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Irbesartan, Internal medicine, Republic of Korea, Drug Discovery, medicine, anti-hypertensive, Drugs, Generic, Humans, 030212 general & internal medicine, Adverse effect, Antihypertensive Agents, Original Research, Aged, Pharmacology, Drug Design, Development and Therapy, Intention-to-treat analysis, business.industry, Incidence (epidemiology), Sitting systolic blood pressure, Middle Aged, medicine.disease, generic medicine, Treatment Outcome, Female, Open label, business, Angiotensin II Type 1 Receptor Blockers, medicine.drug

الوصف: Seung Hwan Han,1 Gyu Chul Oh,2 Hyuck Moon Kwon,3 Chang Gyu Park,4 In Jai Kim,5 Gyo-Seung Hwang,6 Byung Su Yoo,7 Seong Hoon Park,8 Kwang Je Lee,9 Hyo-soo Kim21Division of Cardiology, Department of Internal Medicine, Gachon University College of Medicine, Gil Hospital, Incheon, Republic of Korea; 2Division of Cardiology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; 3Cardiology Division, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; 4Division of Cardiology, Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea; 5Department of Cardiology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea; 6Department of Cardiology, Ajou University School of Medicine, Suwon, Republic of Korea; 7Division of Cardiology, Department of Internal Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea; 8Division of Cardiology, Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Republic of Korea; 9Division of Cardiology, Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Republic of Korea Purpose: This study aimed to compare the efficacy and safety of generic and branded irbesartan for 8 weeks in patients with mild-to-moderate essential hypertension.Patients and methods: We screened 221 patients with mild-to-moderate hypertension. After exclusion per study criteria, 177 subjects were randomized to receive 150 mg generic irbesartan (n=91) or branded irbesartan (n=86) as the intention to treat set. The primary efficacy endpoint of this study was the change in mean sitting diastolic blood pressure (SiDBP) from baseline to 8 weeks between the generic and branded irbesartan groups. The secondary efficacy endpoints were the change in mean SiDBP at Week 4 from baseline and the change in mean sitting systolic blood pressure (SiSBP) at Weeks 4 and 8 from baseline in both groups. All safety issues were evaluated.Results: At Week 8, the generic and branded irbesartan groups showed significantly reduced SiDBP (−10.3±8.0, −10.7±7.7 mmHg, all P

وصف الملف: text/html

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0907cb7b28e392a7f82bd094467f1b3fTest
https://doi.org/10.2147/dddt.s172046Test

المؤلفون: Ning-L, Sun, Jun-R, Zhu, Yanxing, Zhao, Ying-M, Tu, Qi, Bi

المصدر: Current Medical Research and Opinion. 24:2863-2871

مصطلحات موضوعية: Adult, Male, China, medicine.medical_specialty, Time Factors, Combination therapy, Tetrazoles, Sitting diastolic blood pressure, Blood Pressure, Essential hypertension, Hydrochlorothiazide, Asian People, Double-Blind Method, Internal medicine, medicine, Humans, Antihypertensive Agents, Aged, Aged, 80 and over, Chinese population, business.industry, Outcome measures, Valine, Sitting systolic blood pressure, General Medicine, Middle Aged, medicine.disease, Valsartan, Hypertension, Physical therapy, Drug Therapy, Combination, Female, business, medicine.drug

الوصف: To compare the efficacy and safety of valsartan (VAL)/HCTZ 80/12.5 mg with VAL 80 mg in Chinese patients with mild-to-moderate essential hypertension not adequately controlled with VAL 80 mg alone.This was a multicenter, double-blind, double-dummy, randomized, active-controlled, parallel-group trial. Patients (1175) with mild-to-moderate essential hypertension (mean sitting diastolic blood pressure [MSDBP]or = 95 and110 mmHg) from 26 centers in China received VAL 80 mg o.d. for 4 weeks, 864 patients whose MSDBP remainedor = 90 and110 mmHg were randomized (1:1) to receive VAL80/HCTZ12.5 mg (n = 429) or VAL80 mg (n = 435) for 8 weeks.The efficacy variable was changed from baseline to endpoint in trough MSDBP. The secondary efficacy variables were changed in mean sitting systolic blood pressure (MSSBP), response rate, and control rate.Significant reductions in MSDBP and MSSBP from baseline to endpoint were observed in both groups. There were significantly greater reductions in MSDBP (8.4 mmHg vs. 6.2 mmHg) and MSSBP (10.2 mmHg vs. 6.7 mmHg), higher response (64.2% vs. 52.5%) and control rates (53.9% vs. 40.9%) in the VAL80/HCTZ12.5 group as compared with the VAL80 group at endpoint (p0.001). VAL80/HCTZ12.5 was equally effective in both age subgroups (or = 65 and65 years) and was well tolerated. There were no deaths and the two serious adverse events reported were unrelated to study medication.In Chinese patients with mild-to-moderate essential hypertension not adequately controlled by VAL 80 mg alone, VAL80/HCTZ12.5 mg combination was well tolerated and showed additional BP reduction. The limitations of this study were the inability to include an HCTZ arm as a control group and the short trial duration.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cf4b0d032bb67f51269d9887fe61617Test
https://doi.org/10.1185/03007990802390647Test

المؤلفون: Daniel F. Connor, Thomas J. Spencer

المصدر: CNS Spectrums. 10:31-38

مصطلحات موضوعية: medicine.medical_specialty, End point, Pulse (signal processing), business.industry, Sitting systolic blood pressure, Placebo, Psychiatry and Mental health, Blood pressure, Internal medicine, Oppositional defiant, medicine, Cardiology, Neurology (clinical), Extended release, business, Amphetamine, medicine.drug

الوصف: ObjectiveAssess cardiovascular effects of mixed amphetamine salts extended release (MAS XR) in children and adolescents (6–17 years of age) with oppositional defiant disorder (ODD).MethodsA 4-week, double-blind, randomized, placebo-controlled, forced dose-titration study of once-daily 10-, 20-, 30-, or 40-mg MAS XR (n=308). Resting/sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) and pulse were measured at baseline and weekly thereafter. Electrocardiograms (ECGs) were obtained at screening and study end point.FindingsAt study end point, mean changes in SBP and DBP were minimal with MAS XR (SBP: -0.2 to 1.1 mm Hg; DBP: -1.0 to 2.1 mm Hg) and comparable to placebo (SBP: -0.6 mm Hg; DBP: -0.4 mm Hg). Mean end point pulse was similar with MAS XR (80.6–84.7 bpm) and placebo (81.8 bpm). No dose-related trends in blood pressure and pulse changes were observed. No clinically significant changes in ECG parameters were seen with MAS XR. Changes in QTcB (Bazett's formula) interval with MAS XR were small (0.5 to 3.9 msec). No patient discontinued due to a cardiovascular adverse event.ConclusionCardiovascular effects of MAS XR (10–40 mg) were minimal and comparable to those with placebo in children and adolescents with ODD.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::b2569df286efaafb701d21f9ec4399cfTest
https://doi.org/10.1017/s1092852900014127Test

المؤلفون: Hiroya Yamaguchi, Takuya Tsuchihashi, Go Fujimoto, Hirotaka Numaguchi, Chisato Nishida, Kenji P Fujita, Hiromi Rakugi, Kyoichi Azuma, Mary E. Hanson, Masayoshi Shirakawa, Kazuyuki Shimada

المصدر: Hypertension research : official journal of the Japanese Society of Hypertension. 37(12)

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Physiology, Endpoint Determination, Sitting diastolic blood pressure, Essential hypertension, Losartan, law.invention, Young Adult, Hydrochlorothiazide, Randomized controlled trial, Asian People, Double-Blind Method, law, Internal Medicine, medicine, Clinical endpoint, Humans, Diuretics, Antihypertensive Agents, Aged, Aged, 80 and over, business.industry, Sitting systolic blood pressure, Middle Aged, medicine.disease, Surgery, Drug Combinations, Tolerability, Anesthesia, Hypertension, Female, Patient Safety, Essential Hypertension, Cardiology and Cardiovascular Medicine, business, Angiotensin II Type 1 Receptor Blockers, medicine.drug

الوصف: Two randomized studies were designed to assess the safety, tolerability and efficacy of losartan 100 mg (L100) plus hydrochlorothiazide 12.5 mg (H12.5) in a single fixed-dose combination. In one study, subjects received losartan 50 mg (L50) plus H12.5 during an 8-week filter period. They were then randomized to either L100/H12.5 or L50/H12.5 for another 8 weeks, followed by L100/H12.5 for 44 weeks. The primary end point was safety of L100/H12.5 for 52 weeks. In the second study, subjects received L100 during an 8-week filter period. Subjects were then randomized to receive either L100/H12.5 or L100 for a further 8 weeks. The primary end point was change from baseline in sitting diastolic blood pressure (SiDBP) at week 8. Safety was assessed throughout both studies. L100/H12.5 reduced SiDBP and sitting systolic blood pressure (SiSBP) at 8 weeks, and when compared with L100, the differences were statistically significant for both measures (P0.001). L100/H12.5 reductions SiDBP for 8 weeks were comparable to L50/H12.5. The efficacy of L100/H12.5 was maintained to week 52. Drug-related adverse events with an incidence ⩾ 2% in the L100/H12.5 group during the 52-week extension period were an increase in aspartate aminotransferase and in blood uric acid. Additionally, mean uric acid levels were reduced by 0.57 mg dl(-1) from baseline with long-term treatment with L100/H12.5 in subjects whose baseline uric acid level was7.0 mg dl(-1). In conclusion, L100/H12.5 was shown to be more effective than L100 at reducing SiDBP and SiSBP and showed good tolerability in Japanese patients with essential hypertension.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bdb8dcc723d7a108b5fb830fae338abTest
https://pubmed.ncbi.nlm.nih.gov/25185832Test

المؤلفون: Barrett W. Jeffers, Jeffery Robbins, Kazuomi Kario

المصدر: Vascular Health and Risk Management

مصطلحات موضوعية: Male, medicine.medical_specialty, Asia, hypertension, Endocrinology, Diabetes and Metabolism, Vasodilator Agents, Urology, Blood Pressure, Clinical Trials, Phase IV as Topic, amlodipine, Severity of Illness Index, Asian People, Retrospective analysis, Medicine, Humans, Pharmacology (medical), Amlodipine, cardiovascular diseases, Antihypertensive Agents, Aged, Retrospective Studies, Original Research, End point, business.industry, Public Health, Environmental and Occupational Health, Sitting systolic blood pressure, Hematology, General Medicine, Middle Aged, Calcium Channel Blockers, Confidence interval, Surgery, Vascular Health and Risk Management, Blood pressure, Treatment Outcome, Clinical Trials, Phase III as Topic, Western World, Female, Cardiology and Cardiovascular Medicine, business, medicine.drug, circulatory and respiratory physiology

الوصف: Kazuomi Kario,1 Jeffery Robbins,2 Barrett W Jeffers21Division of Cardiovascular Medicine, Jichi Medical University, Shimotsuke, Japan; 2Pfizer, New York, NY, USAAbstract: In this retrospective analysis, data pooled from two Phase III/IV open-label Asian studies were used to quantify the additional blood pressure efficacy achieved when titrating amlodipine from 5 mg to 10 mg in mild/moderate hypertensive patients, and compared to data pooled from three Western studies. The primary efficacy end point was the change from baseline in sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) to the specified time point (4–8 weeks, depending on the trial). For the Asian analysis (n=174), both mean SBP and DBP were significantly decreased at the final visit (SBP -13.3 mmHg, 95% confidence interval [CI] -15.5 to -11.0; DBP -9.2 mmHg, 95% CI -10.6 to -7.8; both P

وصف الملف: text/html

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7c17eb3924ea33a14e79f68d525fa4cTest
https://pubmed.ncbi.nlm.nih.gov/24235839Test

المؤلفون: Ghionul Ibram, Stephanie Le Breton, G. Villa, Deborah L. Keefe

المصدر: Journal of clinical pharmacology. 52(12)

مصطلحات موضوعية: Male, medicine.medical_specialty, Urology, Blood Pressure, Pharmacology, Placebo, Double blind, chemistry.chemical_compound, Double-Blind Method, Fumarates, Medicine, Humans, Pharmacology (medical), Meals, Antihypertensive Agents, Morning, Aged, Meal, End point, Dose-Response Relationship, Drug, business.industry, Sitting systolic blood pressure, Aliskiren, Amides, Treatment Outcome, Tolerability, chemistry, Hypertension, Female, business

الوصف: This randomized, double-blind, placebo-controlled study assessed the efficacy, safety, and tolerability of aliskiren 75, 150, and 300 mg to clarify the dose-response relationship and characterize the optimum aliskiren dose when given with a light meal to elderly hypertensive patients. After washout, 754 patients aged ≥65 years with hypertension (mean sitting systolic blood pressure [msSBP] ≥150 and

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc55322f0de559efd6270f41cc3f1c79Test
https://pubmed.ncbi.nlm.nih.gov/22174431Test

المؤلفون: Mark Greathouse

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Urology, Clinical Investigations, Vasodilation, Placebo, Nebivolol, Placebos, Double-Blind Method, medicine, Humans, In patient, Benzopyrans, Least-Squares Analysis, Adverse effect, Antihypertensive Agents, Aged, Aged, 80 and over, Analysis of Variance, Chi-Square Distribution, business.industry, Sitting systolic blood pressure, General Medicine, Middle Aged, Stage i ii, Treatment Outcome, Tolerability, Ethanolamines, Anesthesia, Hypertension, Female, Cardiology and Cardiovascular Medicine, business, medicine.drug

الوصف: Background Nebivolol is a novel, β1-adrenergic receptor blocker with vasodilatory properties mediated through activation of the L-arginine/nitric oxide pathway. Hypothesis This multicenter, double-blind, parallel-group, placebo-controlled study investigated the antihypertensive efficacy and safety of nebivolol in patients with stage I through stage II hypertension (sitting diastolic blood pressure [SiDBP] ≥ 95 mm Hg and ≤ 109 mm Hg). Methods A total of 811 patients were randomized to placebo or nebivolol 5 mg, 10 mg, or 20 mg once daily for 12 weeks. The primary efficacy endpoint was the reduction in mean trough SiDBP from baseline. Results At study end, the least squares mean reductions in trough SiDBP from baseline with nebivolol 5 mg, 10 mg, and 20 mg were − 7.8 mm Hg, − 8.5 mm Hg, and − 9.1 mm Hg, respectively, compared with − 4.6 mm Hg for placebo (P = .002 for nebivolol 5 mg, P

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e17577dc9e693d280e9eb9370d487bdeTest
https://europepmc.org/articles/PMC6653317Test/

المؤلفون: C Calvo, Antonio Salvetti, L Keeling, P Brunel, Marc G. Weisskopf, Ersin Akpınar, J Schrader

المساهمون: Çukurova Üniversitesi

المصدر: International Journal of Clinical Practice

مصطلحات موضوعية: Male, medicine.medical_specialty, Peripheral edema, Tetrazoles, Internal medicine, Edema, Medicine, Humans, Amlodipine, Antihypertensive Agents, Aged, Original Paper, Amlodipine 5 MG, business.industry, Sitting systolic blood pressure, Valine, General Medicine, Middle Aged, Lower incidence, Drug Combinations, Treatment Outcome, Valsartan, Anesthesia, Hypertension, Cardiology, Female, Amlodipine-Valsartan, medicine.symptom, business, medicine.drug

الوصف: PubMedID: 19196360 Aims: To demonstrate the benefit of the combination amlodipine/valsartan 5/160 mg over amlodipine 10 mg, in producing a lower incidence of peripheral oedema for a comparable mean sitting systolic blood pressure (MSSBP) reduction. Methods: After a 4-week amlodipine 5 mg run-in phase, inadequately controlled hypertension patients (aged ? 55 years, MSSBP ? 130 and ? 160 mmHg) were randomised to receive amlodipine/valsartan 5/160 mg or amlodipine 10 mg for 8 weeks, followed by amlodipine/valsartan 5/160 mg for 4 weeks for all patients. Primary variables were MSSBP change from baseline to week 8 and incidence of peripheral oedema reported as an AE. Resolution of peripheral oedema was assessed 4 weeks after switching patients from amlodipine 10 mg to amlodipine/ valsartan 5/160 mg. Results: At week 8, MSSBP showed greater reduction with amlodipine/valsartan 5/160 mg than amlodipine 10 mg (least square mean: -8.01 vs.-5.95 mmHg, p < 0.001 for non-inferiority and p = 0.002 for superiority). Systolic control, overall BP control and systolic response rate at week 8 were significantly higher with combination than amlodipine 10 mg (34 vs. 26%; 57 vs. 50%; 36.57 vs. 27.77%, respectively). Incidence of peripheral oedema was significantly lower with the combination than amlodipine 10 mg (6.6 vs. 31.1%, p < 0.001). Peripheral oedema resolved in 56% patients who switched from amlodipine 10 mg to the combination, without the loss of effect on BP reduction. Conclusion: In non-responders to amlodipine 5 mg, treatment with amlodipine/valsartan 5/160 mg induced significantly less peripheral oedema than amlodipine 10 mg for similar BP reduction. Peripheral oedema resolved in > 50% patients switching from amlodipine 10 mg to the combination. © 2009 The Authors.Indications:671 patients with refractory essential hypertension. Coexisting disease was diabetes mellitus in 486 patients.Patients:1183 patients. Exforge group: n=592, 307 males and 285 females, mean age 65.6 years; 559 Caucasian and 33 other; 35 dropouts, 14 were due to side effects. Amlodipine 10 mg group: n=591, 307 males and 284 females, mean age 65.4 years; 560 Caucasian, 28 other, 2 Asian and 1 Pacific Islander; 115 dropouts, 84 were due to side effects. Amlodipine switched to Exforge at week 8 group (switched group): n=484.TypeofStudy:A study evaluating the non-inferiority of Exforge compared with amlodipine 10 mg with respect to antihypertensive efficacy, along with the incidence of peripheral edema, in patients with essential hypertension not adequately controlled with amlodipine 5 mg alone. A randomized, multicenter, placebo-controlled, single-blind study for 4 weeks and double blind-study for 12 weeks.DosageDuration:Amlodipine 5 mg and valsartan 160 mg once daily in the morning. Duration was 4-12 weeks.ComparativeDrug:Amlodipine was given at 10 mg once daily in the morning. Duration was 8 weeks.Results:The frequency of discontinuation due to AEs was higher in the amlodipine group (14.2%) vs. Exforge group (2.5%). The least square mean (LSM) reduction of MSSBP with the Exforge group was statistically non-inferior compared with amlodipine group. Non-inferiority was also observed with LSM reductions from baseline at week 4 and 8 in MSSBP and week 8 in MSDBP and at week 12 after the switch from amlodipine to Exforge. The systolic control produced by Exforge was better than amlodipine alone at week 4 and 8, and similar after the switch from amlodipine to Exforge. Overall BP control was attained in a significantly higher proportion of patients in the Exforge group at weeks 4 and 8. The systolic BP response rate was higher with Exforge vs. amlodipine 10 mg at week 4 and 8, and similar after the switch from amlodipine 10 mg to Exforge at week 12. The most frequently reported adverse event (AE) during the study was peripheral edema, which was higher in the amlodipine 10 mg group (31.5%) vs. the Exforge group (7.3%). The severity of peripheral edema was also higher in the amlodipine group vs. the Exforge group. Exforge induced significantly less peripheral edema than amlodipine 10 mg up to and including week 8. The incidence of peripheral edema decreased in both groups from week 8 to 12 (more pronounced in the switched group than in the group that remained on Exforge. Resolution of peripheral edema was observed in more than half of the patients (44 out of 79) after they were switched to Exforge. Resolution of peripheral edema at week 12 was higher in the switched group vs. Exforge group. Both regimens were well tolerated. The overall incidence of AEs was higher in the amlodipine group (55.7%) vs. the Exforge group (43.9%). The second most frequently reported AE was headache (3.2% amlodipine group vs. 2.2% Exforge group). The most frequently reported AE leading to discontinuation was peripheral edema (1% Exforge vs. 11.5% amlodipine), followed by headache (0.2% Exforge vs. 0.5% amlodipine).AdverseEffects:36 and 35 patients in the Exforge group and Switched group, respectively had peripheral edema leading to withdrawal in 5 Exforge-treated patients. 13 Exforge-treated patients had headache leading to withdrawal in 1.AuthorsConclusions:In those hypertensive patients not adequately responding to amlodipine 5 mg monotherapy, the combination of amlodipine/valsartan 5/160 mg induces significantly lesser peripheral oedema for similar BP reductions, and a better safety and tolerability profile than amlodipine 10 mg. In addition, in patients experiencing oedema in the high-dose amlodipine monotherapy arm, more than half resolved after switching to amlodipine/valsartan 5/160 mg. Thus, an effective alternative to amlodipine dose escalation in patients would be a combination of low-dose amlodipine and valsartan, which has a better antihypertensive effect than high-dose amlodipine and a better tolerability profile.FreeText:The mean sitting systolic BP (MSSBP) of all patients was not adequately controlled by amlodipine 5 mg alone and were switched to Exforge or amlodipine 10 mg alone for 8 weeks. At week 8, patients on Exforge continued the same treatment while those on amlodipine 10 mg alone switched to the Exforge group for an additional 4 weeks of treatment. Blood pressure (BP) was monitored (MSSBP and mean sitting diastolic BP [MSDBP]). The occurrence of peripheral edema was assessed.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bc108baf80b8a069f45b201820893ffTest
https://hdl.handle.net/20.500.12605/20821Test

المؤلفون: Bernard Forette, Eric Vicaut, Robert Koen

المصدر: American heart journal. 123(5)

مصطلحات موضوعية: Male, medicine.medical_specialty, medicine.medical_treatment, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Sitting, Hydrochlorothiazide, Oral administration, Heart Rate, Tetrahydroisoquinolines, medicine, Humans, Aged, Aged, 80 and over, Chemotherapy, Analysis of Variance, biology, business.industry, Quinapril, Angiotensin-converting enzyme, Sitting systolic blood pressure, Isoquinolines, Surgery, Blood pressure, Treatment Outcome, Anesthesia, Hypertension, biology.protein, Drug Therapy, Combination, Female, Cardiology and Cardiovascular Medicine, business, medicine.drug

الوصف: The efficacy and safety of once-daily administration of the new angiotensin-converting enzyme inhibitor quinapril or quinapril plus hydrochlorothiazide (HCTZ) were assessed in 64 older (greater than 65 years) patients with mild to moderate hypertension in an uncontrolled, open-label study. Treatment was initiated with 20 mg of quinapril once daily and titrated upward to 40 mg of quinapril or 40 mg of quinapril combined with 25 mg of HCTZ according to efficacy. At the end of the 12-week active-treatment phase, 43 patients received 20 mg of quinapril once daily, 12 patients received 40 mg of quinapril once daily, and 4 patients received 40 mg of quinapril combined with 25 mg of HCTZ once daily. Of 48 patients evaluable for efficacy, the mean decrease from baseline in sitting diastolic blood pressure (DBP) was 12.8 mm Hg; 96% of the patients had a blood pressure reduction of greater than or equal to 10 mm Hg, and 98% had a sitting DBP of less than or equal to 90 mm Hg 20 to 28 hours after administration. The decrease in sitting DBP was significant after 1 week and continued for the entire study, as did corresponding changes in sitting systolic blood pressure. We conclude that quinapril administered once daily is well tolerated and effective for the treatment of mild to moderate hypertension in elderly patients.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c419d3a3e091a7b73c293ff9ea77c97Test
https://pubmed.ncbi.nlm.nih.gov/1575170Test